<DOC>
	<DOCNO>NCT01821846</DOCNO>
	<brief_summary>This trial conduct Asia . The aim study investigate safety profile liraglutide ( Victoza® ) normal condition use Korean subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>Investigating Safety Profile Liraglutide Under Normal Conditions Use Korean Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects T2DM ( Type 2 Diabetes Mellitus ) , include newlydiagnosed subject , require treatment Victoza® accord clinical judgment treat physician Subjects ( and/or parent subject 's legally acceptable representative ) capable give studyspecific sign informed consent collection information Subjects hypersensitivity Victoza® excipients Subjects pregnant , breast feeding intention become pregnant within study period Subjects personal family history medullary thyroid carcinoma ( MTC ) Subjects multiple endocrine neoplasia syndrome type 2 ( MEN2 )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>